Patient Profile 3: A Patient with HER2+ Gastric Cancer Treated With T-DXd–who Develops Neutropenia

High-grade immune-related adverse effects occurred in 18.9% of older patients with early-stage breast cancer treated with immune checkpoint inhibitors, according to a multi-institutional study.

Holly Chitwood, DNP, FNP-C, AGACNP-BC, explains how circulating tumor DNA monitoring helps providers screen minimal residual disease in individuals with colorectal cancer.

Neoadjuvant patritumab deruxtecan demonstrated comparable responses with lower high-grade adverse effects in patients with high-risk, HR–positive, HER2-negative breast cancer.

Ryan Tamargo, NP, AONCP, discusses the launch of an online inflammatory breast cancer scoring system tool.

The phase 3 PANOVA-3 trial, designed to evaluate concomitant treatment with tumor treating fields and chemotherapy, met its primary end point of overall survival in unresectable, locally advanced pancreatic adenocarcinoma.

Most patients with triple-negative breast cancer experienced a protocol-defined immune response with an investigational vaccine, phase 1 data showed.